NOC2L inhibits trophoblast ferroptosis in preeclampsia through the p53/SLC7A11 pathway
Molecular and Cellular Endocrinology · 2025-09 · 607 · 112589
DOI: 10.1016/j.mce.2025.112589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2025-09. Verfasst von Fengyun Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, 271000, Shandong Province, PR China. Hauptthemen laut MEDLINE: Ferroptosis, Trophoblasts, Pre-Eclampsia, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: NOC2L is downregulated in preeclampsia (PE). However, the underlying functional mechanisms of NOC2L in the pathogenesis of PE remain unclear. METHODS: Cell viability, migration, and invasion were determined in hypoxia-stimulated HTR-8/SVneo cells in CCK-8, wound healing, and Transwell assays. The levels of GSH, MDA and Fe2+ were measured using specific commercial kits. Lipid ROS levels were determined through C11-BODIPY staining. The protein levels were analyzed via western blotting. Additionally, a rat model of PE was used to examine the influence of NOC2L on the progression of PE and the associated ferroptosis. RESULTS: NOC2L overexpression increased the viability of hypoxia-treated trophoblast cells and increased the levels of GSH, SLC7A11, and GPX4 while simultaneously reducing Fe2+, MDA, and lipid ROS levels. Furthermore, both NOC2L overexpression and ferrostatin-1 application facilitated trophoblast migration and invasion. In contrast, NOC2L knockdown exacerbated the hypoxia-induced increase in ferroptosis and inhibited cell migratory and invasive capabilities. Notably, treatment with PFT-α, a p53 inhibitor, abolished the influence of NOC2L silencing on trophoblast cell functions. NOC2L overexpression was associated with improved blood pressure and urinary protein concentration, reduced pathological damage in the placenta, alterations in ferroptosis-related markers, and an increased survival rate in rat fetuses. CONCLUSION: NOC2L inhibits trophoblast ferroptosis through the p53/SLC7A11 signaling pathway, potentially preventing the progression of PE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, 271000, Shandong Province, PR China.
- Department of Obstetrics, Taian Maternal and Child Health Hospital, Tai'an, 271000, Shandong Province, PR China.
- Department of Obstetrics and Gynecology, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213000, Jiangsu Province, PR China.
- Department of Obstetrics, Taian Central Hospital Affiliated to Qingdao University, Tai'an, 271000, Shandong Province, PR China.
- Department of Obstetrics, Taian Central Hospital Affiliated to Qingdao University, Tai'an, 271000, Shandong Province, PR China. Electronic address: 13371017177@163.com.
- Department of Obstetrics, Taian Central Hospital Affiliated to Qingdao University, Tai'an, 271000, Shandong Province, PR China. Electronic address: zxd19811108@126.com.
Zitieren
APA
Su, F., Shi, F., Yang, C., Zhao, F., Geng, X., Yang, X., & Zhao, X. (2025). NOC2L inhibits trophoblast ferroptosis in preeclampsia through the p53/SLC7A11 pathway. Molecular and Cellular Endocrinology, 607, 112589. https://doi.org/10.1016/j.mce.2025.112589
Vancouver
Su F, Shi F, Yang C, Zhao F, Geng X, Yang X, et al. NOC2L inhibits trophoblast ferroptosis in preeclampsia through the p53/SLC7A11 pathway. Molecular and Cellular Endocrinology. 2025;607:112589. doi:10.1016/j.mce.2025.112589
BibTeX
@article{Su2025,
author = {Su, Fengyun and Shi, Fanhua and Yang, Chun and Zhao, Fei and Geng, Xiaolin and Yang, Xiaojing and Zhao, Xudong},
title = {NOC2L inhibits trophoblast ferroptosis in preeclampsia through the p53/SLC7A11 pathway},
journal = {Molecular and Cellular Endocrinology},
year = {2025},
volume = {607},
pages = {112589},
doi = {10.1016/j.mce.2025.112589}
}
EUVIMED